Halozyme Therapeutics acquires Surf Bio

Halozyme Therapeutics agreed to acquire Surf Bio. Reported deal value: $400M. Status: Completed. Sector: Biopharmaceutical. Target headquarters context: Palo Alto, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-02. Figures and status may change as filings and press coverage update.

January 28 , 2026 Fenwick Represents Surf Bio in $ 400M Acquisition by Halozyme Fenwick represented Surf Bio , a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in its acquisition by Halozyme Therapeutics , Inc. , a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies